Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno‐Oncology and Beyond: Challenges, Perspectives, and Prospects

(2020) Haiqing Isaac Dai et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first line immunochemotherapy

(2019) Candice Jamois et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance

(2018) David Turner et al.   CLINICAL CANCER RESEARCH

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

(2017) Annalisa Chiappella et al.   LANCET ONCOLOGY

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

(2017) Andrew Davies et al.   Lancet Haematology

Population pharmacokinetics (PK) and association of PK and clinical outcomes of rituximab in patients with non-Hodgkin's lymphoma.

(2017) A. Yin et al.   JOURNAL OF CLINICAL ONCOLOGY

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

(2016) M. Rummel et al.   ANNALS OF ONCOLOGY

Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial

(2016) Sarit Assouline et al.   Lancet Haematology

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries

(2016) Erwin De Cock et al.   PLoS One

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

(2015) K. Fischer et al.   BLOOD

Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia

(2015) Sarit Assouline et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL

(2014) N. Murawski et al.   ANNALS OF ONCOLOGY

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study

(2014) Andrew Davies et al.   LANCET ONCOLOGY

Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration

(2012) Wolfgang F. Richter et al.   AAPS Journal

Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia

(2012) Jing Li et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

Standardized Visual Predictive Check Versus Visual Predictive Check for Model Evaluation

(2011) Diane D. Wang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions

(2009) Radojka M. Savic et al.   AAPS Journal

Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look

(2009) Jie Ling et al.   JOURNAL OF CLINICAL PHARMACOLOGY